News

Manchester and London, UK, 23 September, 2014 – C4X Discovery (C4XD), a leader in rational drug discovery and design, today announced further positive data from its Orexin-1 programme to treat stress-related addictive disorders.

Manchester and London, UK, 8 September, 2014 – C4X Discovery (C4XD), a leader in rational drug discovery and design, announced today that it has signed a research collaboration agreement under which C4XD's proprietary NMR-based technology will be applied across a number of Evotec's pre-clinical therapeutic projects to enhance lead discovery and hit identification.

Manchester and London, UK, 4 September, 2014 – C4X Discovery (C4XD), a leader in rational drug discovery and design, today announced positive initial data from its Orexin-1 programme to treat stress-related addictive disorders, and the filing of a related patent.

Manchester and London, UK, 26 August, 2014 – C4X Discovery (C4XD), a leader in rational drug discovery and design, announced today that it has signed a research collaboration agreement with Takeda Cambridge Limited ("TCB"), a UK subsidiary of Takeda Pharmaceutical Company Limited, the largest pharmaceutical company in Japan. Under the agreement, C4XD's proprietary NMR-based technology will be applied across a number of TCB's therapeutic projects to enhance lead discovery and hit identification.

Manchester and London, UK, 4 July, 2014 – C4X Discovery (C4XD), a leader in rational drug discovery and design, today announced that its patent relating to a new method for determining the three-dimensional structures of dynamic molecules has been granted in Japan.

Manchester and London, UK, 4 July, 2014 – C4X Discovery (C4XD), a leader in rational drug discovery and design, today announced that it has won a grant from the UK's innovation agency, the Technology Strategy Board.

Manchester and London, UK, 24 June, 2014 – C4X Discovery (C4XD), a leader in rational drug discovery and design, today announced the publication of a new peer-reviewed paper in the Journal of Medicinal Chemistry (“JMedChem”). JMedChem is published by the American Society of Chemistry and is widely regarded as one of the leading publications for research and development. The paper was co-authored with researchers from C4XD’s collaboration partner, AstraZeneca, and Pharmaron Beijing Co Ltd.

Manchester and London, UK, 11 June, 2014 – C4X Discovery (C4XD), a leader in rational drug discovery and design, today announced the appointment of Piers Morgan as Chief Executive Officer with immediate effect. Mr Morgan has also been appointed to the Company's Board of Directors. He succeeds Dr Sam Williams, who returns to his previous role as a Non-Executive Director of the Company.